Latest news

• Biohaven gets FDA approval for migraine drug Nurtec ODT

  A successful outcome in those studies would make the drug a potential competitor to three CGRP inhibitors given by subcutaneous injection – Amgen/Novartis’ Aimovig (erenumab), Teva’s Ajovy (fremanezumab) and

• Lundbeck gets US approval for migraine drug at heart of Alder takeover

  It’s also the first and only intravenously-administered CGRP antibody, as the current three drugs – Amgen/Novartis’ Aimovig (erenumab), Teva’s Ajovy (fremanezumab) and Eli Lilly’s Emgality (galcanezumab) – are

• Lilly launches migraine med Reyvow at $640 per eight-pill pack

  Lilly’s other migraine med – CGRP antagonist Emgality (galcanezumab) – has begun to establish itself in the prevention category, but still lags behind first-in-class Aimovig (erenumab) from Novartis and

• Allergan gets FDA nod for first oral CGRP drug for migraine

  First to market among these the injectables was Amgen/Novartis’ Aimovig (erenumab), and it has since been joined by Eli Lilly’s Emgality (galcanezumab) and Teva’s Ajovy (fremanezumab), with intravenous

• Amgen exits neuroscience R&D to focus on growth areas

  The unit scored a victory with the recent approval and launch of chronic migraine drug  Aimovig (erenumab), but earlier this year was forced to abandon its  umibecestat candidate for Alzheimer’s